Accéder au contenu
Merck

Membrane type 1 matrix metalloproteinase promotes LDL receptor shedding and accelerates the development of atherosclerosis.

Nature communications (2021-03-27)
Adekunle Alabi, Xiao-Dan Xia, Hong-Mei Gu, Faqi Wang, Shi-Jun Deng, Nana Yang, Ayinuer Adijiang, Donna N Douglas, Norman M Kneteman, Yazhuo Xue, Li Chen, Shucun Qin, Guiqing Wang, Da-Wei Zhang
RÉSUMÉ

Plasma low-density lipoprotein (LDL) is primarily cleared by LDL receptor (LDLR). LDLR can be proteolytically cleaved to release its soluble ectodomain (sLDLR) into extracellular milieu. However, the proteinase responsible for LDLR cleavage is unknown. Here we report that membrane type 1-matrix metalloproteinase (MT1-MMP) co-immunoprecipitates and co-localizes with LDLR and promotes LDLR cleavage. Plasma sLDLR and cholesterol levels are reduced while hepatic LDLR is increased in mice lacking hepatic MT1-MMP. Opposite effects are observed when MT1-MMP is overexpressed. MT1-MMP overexpression significantly increases atherosclerotic lesions, while MT1-MMP knockdown significantly reduces cholesteryl ester accumulation in the aortas of apolipoprotein E (apoE) knockout mice. Furthermore, sLDLR is associated with apoB and apoE-containing lipoproteins in mouse and human plasma. Plasma levels of sLDLR are significantly increased in subjects with high plasma LDL cholesterol levels. Thus, we demonstrate that MT1-MMP promotes ectodomain shedding of hepatic LDLR, thereby regulating plasma cholesterol levels and the development of atherosclerosis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-MMP-14, domaine catalytique, clone LEM-2/15.8, clone LEM-2/15.8, Chemicon®, from mouse
Sigma-Aldrich
Anti-MMP-14 Antibody, catalytic domain, clone LEM-2/63.1, clone LEM-2/63.1, Chemicon®, from mouse